Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

BACKGROUND: The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xuan, Tu, Sanfang, Wang, Chunsheng, Huang, Rui, Deng, Lan, Song, Chaoyang, Yue, Chunyan, He, Yanjie, Yang, Jilong, Liang, Zhao, Wu, Anqin, Li, Meifang, Zhou, Weijun, Du, Jingwen, Guo, Zhenling, Li, Yongqian, Jiao, Cheng, Liu, Yuchen, Chang, Lung-Ji, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731732/
https://www.ncbi.nlm.nih.gov/pubmed/33329526
http://dx.doi.org/10.3389/fimmu.2020.564099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731732/
https://www.ncbi.nlm.nih.gov/pubmed/33329526
http://dx.doi.org/10.3389/fimmu.2020.564099

Ejemplares similares